For informational purposes only.
Glypten tablet
Glypten tablet is prescribed to control high blood sugar levels in type 2 diabetes mellitus for adult patients above 18 years of age.
Glypten Tablet Composition :-
Teneligliptin ..................................... 20mg
Glypten Tablet Uses :-
Glypten tablet is an antidiabetic drugs, used to control type 2 diabetes mellitus (high blood sugar levels) in adult patients above 18 years of age.
Glypten
tablet can be used alone or in combination with other antidiabetic drugs.
When Glypten
tablet is used along with a healthy diet and exercise, it helps a lot in controlling blood sugar.
Dosage Forms & Strengths :-
Glypten Tablet Dosage :-
Glypten
tablet is a prescription medicine. Take Glypten
tablet as directed by your doctor. Use Glypten
tablet exactly as directed by the doctor. Do not take a higher or lower dose than directed by your doctor. Glypten
tablet should be taken immediately before or with a meal. Never self-medicate or change the dosage without a doctor's advice.
Do not take 2 or more doses at the same time.
Always try to take Glypten tablet on regular schedule. Always take the tablet even if you feel well or your blood sugar level is under control. Do not stop taking without your doctor's advice. Otherwise, your blood sugar level may rise again. Do not stop taking Glypten tablet without asking your doctor. Because the treatment of diabetes is lifelong.
How Does Glypten tablet ( Teneligliptin ) Work :-
Glypten
tablet contains : Teneligliptin.
Teneligliptin :
Teneligliptin is an dipeptidyl peptidase 4 (DPP-4) inhibitors class antidiabetic drugs. Teneligliptin works by increasing the amount of insulin produced by pancreas. Teneligliptin works by decreasing the hormones that raise blood sugar levels in the pancreas. Teneligliptin lowers your blood sugar level, and controls the amount of glucose in the blood.
Thus Glypten tablet works by controlling the level of sugar in the blood.
Glypten Tablet Sideeffects :-
Low blood sugar (hypoglycemia),
Constipation,
Dizziness,
Diarrhea,
Fever,
Precautions :-
Pregnancy :
Teneligliptin should not be used in pregnant women. If the medical benefits outweigh the potential risks associated with the treatment. Because in animal studies (mice) transferor has been reported to the fetus
Lactation :
For lactating women or during breastfeeding use only if prescribed by a doctor. Because it is unsafe to use during breastfeeding, or breastfeeding should be stopped.
Pediatric Use :
in a low birth weight baby, newborn, infant, or young child The safety of teneligliptin has not been established.
Geriatric Use :
Elderly patients often usually have physiological hypofunction; Teneligliptin should therefore be administered with caution.
Use in patients with renal Impairment :
Teneligliptin is safe to use in patients with renal impairment, as there is no significant risk associated with increased exposure to teneligliptin in patients with renal impairment. And no dosage adjustment is proposed in patients with renal impairment.
Use in patients with hepatic impairment :
Teneligliptin is safe to use in patients with hepatic impairment because the extent of increased exposure to teneligliptin in patients with mild to moderate hepatic impairment does not pose any significant risk. And no dosage adjustment is proposed in patients with mild to moderate hepatic impairment. No experience is available on the use of teneligliptin in patients with severe hepatic impairment.
Glypten tablet Price:-
MRP ₹ : 119.56 ( 10 tabs )
MRP ₹ : 119.56 ( 10 tabs )
Packing Information :-
Glypten
tablet is available in pack of 10 tablets.
Glypten
tablet is available in pack of 10 tablets.
Glypten tablet Marketed By :-
Franco-Indian Pharmaceuticals Pvt Ltd
Franco-Indian Pharmaceuticals Pvt Ltd
Glypten tablet Self life :-
Please see the expiry date/manufacture date printed on Glypten
tablet pack.
Please see the expiry date/manufacture date printed on Glypten
tablet pack.
Classification :-
Therapeutic Class - Antidiabetic drugs, Dipeptidyl peptidase 4 (DPP-4) inhibitors,
Information on this page was last updated on 17 September 2021